[HTML][HTML] Discovery and development of safe-in-man broad-spectrum antiviral agents

PI Andersen, A Ianevski, H Lysvand… - International Journal of …, 2020 - Elsevier
Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-
specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases …

A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval

NA Ashour, A Abo Elmaaty, AA Sarhan… - Drug design …, 2023 - Taylor & Francis
The rising outbreak of SARS-CoV-2 continues to unfold all over the world. The development
of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some …

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

KT Choy, AYL Wong, P Kaewpreedee, SF Sia, D Chen… - Antiviral research, 2020 - Elsevier
Highlights•Remdesivir inhibits SARS-CoV-2 replication in Vero-E6 cells with EC 50 at 23.15
μM.•Lopinavir but not ritonavir inhibits SARS-CoV-2 replication with EC 50 at 26.63 μM.• …

Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing …

I Mercurio, V Tragni, F Busto, A De Grassi… - Cellular and Molecular …, 2021 - Springer
The recent severe acute respiratory syndrome, known as Coronavirus Disease 2019
(COVID-19) has spread so much rapidly and severely to induce World Health Organization …

Potential antiviral options against SARS-CoV-2 infection

A Ianevski, R Yao, MH Fenstad, S Biza, E Zusinaite… - Viruses, 2020 - mdpi.com
As of June 2020, the number of people infected with severe acute respiratory coronavirus 2
(SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the …

[HTML][HTML] Recent advances in developing small-molecule inhibitors against SARS-CoV-2

R Xiang, Z Yu, Y Wang, L Wang, S Huo, Y Li… - … Pharmaceutica Sinica B, 2022 - Elsevier
The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across
the entire world. Even though several COVID-19 vaccines are currently in distribution …

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

Y Chen, TB Lear, JW Evankovich, MB Larsen… - Nature …, 2021 - nature.com
Abstract SARS-CoV-2 (2019-nCoV) is the pathogenic coronavirus responsible for the global
pandemic of COVID-19 disease. The Spike (S) protein of SARS-CoV-2 attaches to host lung …

Berberine and obatoclax inhibit SARS-Cov-2 replication in primary human nasal epithelial cells in vitro

FS Varghese, E van Woudenbergh, GJ Overheul… - Viruses, 2021 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a new human
pathogen in late 2019 and it has infected over 100 million people in less than a year. There …

A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors

P Ren, W Shang, W Yin, H Ge, L Wang… - Acta Pharmacologica …, 2022 - nature.com
The COVID-19, caused by SARS-CoV-2, is threatening public health, and there is no
effective treatment. In this study, we have implemented a multi-targeted anti-viral drug …

Different aspects of emetine's capabilities as a highly potent SARS-CoV-2 inhibitor against COVID-19

M Valipour - ACS Pharmacology & Translational Science, 2022 - ACS Publications
In the global movement to find the appropriate agents to fight the coronavirus disease of
2019 (COVID-19), emetine is one of the strongest anti-SARS-CoV-2 compounds with sub …